Invivoscribe PrepQuant: Streamlining Clinical DNA Extraction

The liquid biopsy space continues to grow and heat up - just this week Roche's Foundation Medicine unit announced the acquisition of Minimal Residual Disease (MRD) test developer Saga Diagnostics for just over a half billion dollars. Numerous MRD and Multi-Cancer Early Detection (MCED) companies continue to spring up, with even more analyte types - first it was cell-free DNA, but now cell-free RNA…